Skip to main content

Table 2 Previous COVID-19 infection

From: Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases

 

Sum

n = 64

Controls

n = 24

Adolescents with RD n = 40

p

Reported COVID-19 infection

SARS-CoV-2 + PCR n (%)

8 (13%)

4 (18%)

4 (10%)

 

Demonstrated COVID-19 infection

IFNM cellular response n (%)

24 (42%)

8 (34%)

16 (40%)

0.78

SARS-CoV-2 + PCR with

negative IFN-γ M response (n)

2

1

1

 

Global SARS-CoV-2 infection

26/64 (40%)

9/24

(37%)

17/40

(42%)

 

Previously unknown

SARS-CoV-2 infection n (%)

18/26 (70%)

5/9

(55%)

13/17

(76%)